Letters to the Editor Open access

After what time interval are we justified to diagnose immune checkpoint inhibitor-mediated polymyalgia rheumatica?

Authors

Published
3 March 2025
Section
Letters to the Editor
DOI
10.4081/reumatismo.2025.1823

Abstract

Dear Editor,
The number of cases of cancer patients diagnosed as having immune checkpoint inhibitor-mediated polymyalgia rheumatica is increasing...

Keywords

References

  1. Hysa E, Casabella A, Gotelli E, Campitiello R, Schenone C, Genova C, et al. Polymyalgia rheumatica and giant cell arteritis induced by immune checkpoint inhibitors: a systematic literature review highlighting differences from the idiopathic forms. Autoimmun Rev 2024; 23: 103589. DOI: https://doi.org/10.1016/j.autrev.2024.103589
  2. Kostine M, Finckh A, Bingham CO, Visser K, Leipe J, SchulzeKoops H, et al. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Ann Rheum Dis 2021; 80: 36-48. DOI: https://doi.org/10.1136/annrheumdis-2020-217139
  3. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reaction. Clin Pharmacol Ther 1981; 30: 239-45. DOI: https://doi.org/10.1038/clpt.1981.154
  4. Manzo C, Natale M, Isetta M, Castagna A. Comment on: immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement. Rheumatology 2025; 64: 900-1. DOI: https://doi.org/10.1093/rheumatology/keae259
  5. Manzo C, Isetta M. Back to the future: identification and classification of polymyalgia rheumatica and polymyalgia rheumatica-like syndromes following cancer immunotherapy with checkpoint inhibitors. Reumatologia 2021; 59: 62-3. DOI: https://doi.org/10.5114/reum.2021.102600

Metrics

Citations and online attention from Dimensions, Altmetric and PlumX.

PlumX Metrics

License

Copyright (c) 2025 the Author(s)

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.